Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis

Key Points

• To evaluate the effectiveness of various antihyperglycemic therapies in preventing liver-specific events in patients with type 2 diabetes.
• Conducted a network meta-analysis of randomized trials
• Assessed different antihyperglycemic drug classes
• Compared liver-specific risk reduction across therapies
• Found that liver risk reduction varies significantly among antihyperglycemic drug classes
• Indicated the need for further randomized trials to verify drug effects

Abstract